Metastasis suppression by BRMS1 associated with SIN3 chromatin remodeling complexes

Cancer and Metastasis Reviews

Volumn 31, Issue 3-4, 2012, Pages 641-651

  Hurst, Douglas R ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

BRMS1; Chromatin remodeling; Epigenetic; HDAC; Metastasis suppression; SIN3

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BREAST CANCER METASTASIS SUPPRESSOR 1 PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN SIN3; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR GATA 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GROWTH; CANCER INHIBITION; CELL ADHESION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOME 11; CHROMOSOME ANALYSIS; COMPETITIVE INHIBITION; CPG ISLAND; DISEASE ASSOCIATION; DNA MODIFICATION; DOWN REGULATION; DRUG TREATMENT FAILURE; GENE MAPPING; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; KARYOTYPE; LUNG METASTASIS; MELANOCYTE; MELANOMA; METASTASIS; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION REGULATION; TUMOR MICROENVIRONMENT; UPREGULATION;

ANIMALS; CHROMATIN ASSEMBLY AND DISASSEMBLY; HISTONE DEACETYLASE INHIBITORS; HUMANS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; SIN3 HISTONE DEACETYLASE AND COREPRESSOR COMPLEX; TUMOR SUPPRESSOR PROTEINS;

EID: 84867986966     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-012-9363-y     Document Type: Article

References (106)

1. Hanahan, D.; & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646-674.
2. Hurst, D. R.; & Welch, D. R. (2011). Metastasis suppressor genes: at the interface between the environment and tumor cell growth. International Review of Cell and Molecular Biology, 286, 107-180.
3. Langley, R. R.; & Fidler, I. J. (2007). Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocrine Reviews, 28(3), 297-321.
4. Langley, R. R.; & Fidler, I. J. (2011). The seed and soil hypothesis revisitedthe role of tumor-stroma interactions in metastasis to different organs. International Journal of Cancer, 128(11), 2527-2535.
5. Nguyen, D. X.; Bos, P. D.; & Massague, J. (2009). Metastasis: from dissemination to organ-specific colonization. Nature Reviews Cancer, 9(4), 274-284.
6. Sethi, N.; & Kang, Y. (2011). Unravelling the complexity of metastasismolecular understanding and targeted therapies. Nature Reviews. Cancer, 11(10), 735-748.
7. Rodriguez-Paredes, M.; & Esteller, M. (2011). Cancer epigenetics reaches mainstream oncology. Nature Medicine, 17(3), 330-339.
8. Xue, Y.; Wong, J.; Moreno, G. T.; Young, M. K.; Cote, J.; & Wang, W. (1998). NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. Molecular Cell, 2(6), 851-861.
9. Li, D. Q.; Pakala, S. B.; Nair, S. S.; Eswaran, J.; & Kumar, R. (2012). Metastasis-associated protein 1/nucleosome remodeling and histone deacetylase complex in cancer. Cancer Research, 72(2), 387-394.
10. Gupta, R. A.; Shah, N.; Wang, K. C.; Kim, J.; Horlings, H. M.; Wong, D. J.; et al. (2010). Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature, 464(7291), 1071-1076.
11. Tsai, M. C.; Manor, O.; Wan, Y.; Mosammaparast, N.; Wang, J. K.; Lan, F.; et al. (2010). Long noncoding RNA as modular scaffold of histone modification complexes. Science, 329(5992), 689-693.
12. Wang, Y.; Zhang, H.; Chen, Y. P.; Sun, Y. M.; Yang, F.; Yu, W. H.; et al. (2009). LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell, 138(4), 660-672.
13. Crawford, N. P.; Qian, X.; Ziogas, A.; Papageorge, A. G.; Boersma, B. J.; Walker, R. C.; et al. (2007). Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis. PLoS Genetics, 3(11), e214.
14. Crawford, N. P. S.; Yang, H. L.; Mattaini, K. R.; & Hunter, K. W. (2009). The metastasis efficiency modifier ribosomal RNA processing 1 homolog B (RRP1B) is a chromatin-associated factor. Journal of Biological Chemistry, 284(42), 28660-28673.
15. Silverstein, R. A.; & Ekwall, K. (2005). Sin3: a flexible regulator of global gene expression and genome stability. Current Genetics, 47(1), 1-17.
16. Grzenda, A.; Lomberk, G.; Zhang, J. S.; & Urrutia, R. (2009). Sin3: master scaffold and transcriptional corepressor. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms, 1789(6-8), 443-450.
17. McDonel, P.; Costello, I.; & Hendrich, B. (2009). Keeping things quiet: roles of NuRD and Sin3 co-repressor complexes during mammalian development. The International Journal of Biochemistry & Cell Biology, 41(1), 108-116.
18. Phillips, K. K.; Welch, D. R.; Miele, M. E.; Lee, J.-H.; Wei, L. L.; & Weissman, B. E. (1996). Suppression of MDA-MB-435 breast carcinoma cell metastasis following the introduction of human chromosome 11. Cancer Research, 56(10), 1222-1226.
19. Negrini, M.; Rasio, D.; Hampton, G. M.; Sabbioni, S.; Rattan, S.; Carter, S. L.; et al. (1995). Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: identification of a new region at 11q23.3. Cancer Research, 55(14), 3003-3007.
20. Gudmundsson, J.; Barkardottir, R. B.; Eiriksdottir, G.; Baldursson, T.; Arason, A.; Egilsson, V.; et al. (1995). Loss of heterozygosity at chromosome 11 in breast cancer: association of prognostic factors with genetic alterations. British Journal of Cancer, 72(3), 696-701.
21. Hampton, G. M.; Mannermaa, A.; Winquist, R.; Alavaikko, M.; Blanco, G.; Taskinen, P. J.; et al. (1994). Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3. Cancer Research, 54(17), 4586-4589.
22. Devilee, P.; van den Broek, M.; Mannens, M.; Slater, R.; Cornelisse, C. J.; Westerveld, A.; et al. (1991). Differences in patterns of allelic loss between two common types of adult cancer, breast and colon carcinoma, and Wilms' tumor of childhood. International Journal of Cancer, 47(6), 817-821.
23. Seraj, M. J.; Samant, R. S.; Verderame, M. F.; & Welch, D. R. (2000). Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Research, 60(11), 2764-2769.
24. Robertson, G.; Coleman, A.; & Lugo, T. G. (1996). A malignant melanoma tumor suppressor on human chromosome 11. Cancer Research, 56(19), 4487-4492.
25. Shevde, L. A.; Samant, R. S.; Goldberg, S. F.; Sikaneta, T.; Alessandrini, A.; Donahue, H. J.; et al. (2002). Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. Experimental Cell Research, 273(2), 229-239.
26. Zhang, S.; Lin, Q. D.; & Di, W. (2006). Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1. International Journal of Gynecological Cancer, 16(2), 522-531.
27. Smith, P. W.; Liu, Y.; Siefert, S. A.; Moskaluk, C. A.; Petroni, G. R.; & Jones, D. R. (2009). Breast cancer metastasis suppressor 1 (BRMS1) suppresses metastasis and correlates with improved patient survival in non-small cell lung cancer. Cancer Letters, 276(2), 196-203.
28. Seraj, M. J.; Harding, M. A.; Gildea, J. J.; Welch, D. R.; & Theodorescu, D. (2001). The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clinical & Experimental Metastasis, 18(6), 519-525.
29. Samant, R. S.; Debies, M. T.; Shevde, L. A.; Verderame, M. F.; & Welch, D. R. (2002). Identification and characterization of murine ortholog (Brms1) of breast cancer metastasis suppressor 1 (BRMS1). International Journal of Cancer, 97(1), 15-20.
30. Samant, R. S.; Debies, M. T.; Hurst, D. R.; Moore, B. P.; Shevde, L. A.; & Welch, D. R. (2006). Suppression of murine mammary carcinoma metastasis by the murine ortholog of breast cancer metastasis suppressor 1 (Brms1). Cancer Letters, 235(2), 260-265.
31. Hunter, K. W.; Broman, K. W.; LeVoyer, T.; Lukes, L.; Cozma, D.; Debies, M. T.; et al. (2001). Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms1. Cancer Research, 61(24), 8866-8872.
32. Park, Y. G.; Lukes, L.; Yang, H.; Debies, M. T.; Samant, R. S.; Welch, D. R.; et al. (2002). Comparative sequence analysis in eight inbred strains of the metastasis modifier QTL candidate gene Brms1. Mammalian Genome, 13(6), 289-292.
33. Cook, L. M.; Cao, X.; Dowell, A. E.; Debies, M. T.; Edmonds, M. D.; Beck, B. H.; et al. (2012). Ubiquitous Brms1 expression is critical for mammary carcinoma metastasis suppression via promotion of apoptosis. Clinical & Experimental Metastasis, 29(4), 315-325.
34. Metge, B. J.; Frost, A. R.; King, J. A.; Dyess, D. L.; Welch, D. R.; Samant, R. S.; et al. (2008). Epigenetic silencing contributes to the loss of BRMS1 expression in breast cancer. Clinical & Experimental Metastasis, 25(7), 753-763.
35. Hurst, D. R.; Xie, Y.; Edmonds, M. D.; & Welch, D. R. (2009). Multiple forms of BRMS1 are differentially expressed in the MCF10 isogenic breast cancer progression model. Clinical & Experimental Metastasis, 26(1), 89-96.
36. Kim, B.; Nam, H. J.; Pyo, K. E.; Jang, M. J.; Kim, I. S.; Kim, D.; et al. (2011). Breast cancer metastasis suppressor 1 (BRMS1) is destabilized by the Cul3-SPOP E3 ubiquitin ligase complex. Biochemical and Biophysical Research Communications, 415(4), 720-726.
37. Suryadinata, R.; Sadowski, M.; Steel, R.; & Sarcevic, B. (2011). Cyclin-dependent kinase-mediated phosphorylation of RBP1 and pRb promotes their dissociation to mediate release of the SAP30.mSin3.HDAC transcriptional repressor complex. Journal of Biological Chemistry, 286(7), 5108-5118.
38. Li, Z.; David, G.; Hung, K. W.; DePinho, R. A.; Fu, A. K.; & Ip, N. Y. (2004). Cdk5/p35 phosphorylates mSds3 and regulates mSds3-mediated repression of transcription. Journal of Biological Chemistry, 279(52), 54438-54444.
39. Rivera, J.; Megias, D.; Navas, C.; & Bravo, J. (2009). Identification of essential sequences for cellular localization in BRMS1 metastasis suppressor. PLoS One, 4(7), e6433.
40. Silveira, A. C.; Hurst, D. R.; Vaidya, K. S.; Ayer, D. E.; & Welch, D. R. (2008). Over-expression of the BRMS1 family member SUDS3 does not suppress metastasis of human cancer cells. Cancer Letters, 276(1), 32-37.
41. Nikolaev, A. Y.; Papanikolaou, N. A.; Li, M.; Qin, J.; & Gu, W. (2004). Identification of a novel BRMS1-homologue protein p40 as a component of the mSin3A/p33(ING1b)/HDAC1 deacetylase complex. Biochemical and Biophysical Research Communications, 323(4), 1216-1222.
42. Hurst, D. R.; & Welch, D. R. (2011). Unraveling the enigmatic complexities of BRMS1-mediated metastasis suppression. FEBS Letters, 585(20), 3185-3190.
43. Phadke, P. A.; Vaidya, K. S.; Nash, K. T.; Hurst, D. R.; & Welch, D. R. (2008). BRMS1 suppresses breast cancer experimental metastasis to multiple organs by inhibiting several steps of the metastatic process. American Journal of Pathology, 172(3), 809-817.
44. Saunders, M. M.; Seraj, M. J.; Li, Z. Y.; Zhou, Z. Y.; Winter, C. R.; Welch, D. R.; et al. (2001). Breast cancer metastatic potential correlates with a breakdown in homospecific and heterospecific gap junctional intercellular communication. Cancer Research, 61(5), 1765-1767.
45. Kapoor, P.; Saunders, M. M.; Li, Z.; Zhou, Z.; Schaeffer, N.; Kunze, E. L.; et al. (2004). Breast cancer metastatic potential: correlation with increased heterotypic gap junctional intercellular communication between breast cancer cells and osteoblastic cells. International Journal of Cancer, 111(5), 693-697.
46. DeWald, D. B.; Torabinejad, J.; Samant, R. S.; Johnston, D.; Erin, N.; Shope, J. C.; et al. (2005). Metastasis suppression by breast cancer metastasis suppressor 1 involves reduction of phosphoinositide signaling in MDA-MB-435 breast carcinoma cells. Cancer Research, 65(3), 713-717.
47. Vaidya, K. S.; Harihar, S.; Stafford, L. J.; Hurst, D. R.; Hicks, D. G.; Casey, G.; et al. (2008). Breast cancer metastasis suppressor-1 differentially modulates growth factor signaling. Journal of Biological Chemistry, 283(42), 28354-28360.
48. Bodenstine, T. M.; Vaidya, K. S.; Ismail, A.; Beck, B. H.; Cook, L. M.; Diers, A. R.; et al. (2010). Homotypic gap junctional communication associated with metastasis suppression increases with PKA activity and is unaffected by PI3K inhibition. Cancer Research, 70(23), 10002-10011.
49. Champine, P. J.; Michaelson, J.; Weimer, B.; Welch, D. R.; & DeWald, D. B. (2007). Microarray analysis reveals potential mechanisms of BRMS1-mediated metastasis suppression. Clinical & Experimental Metastasis, 24(7), 551-565.
50. Cicek, M.; Samant, R. S.; Kinter, M.; Welch, D. R.; & Casey, G. (2004). Identification of metastasis-associated proteins through protein analysis of metastatic MDA-MB-435 and metastasis-suppressed BRMS1 transfected-MDA-MB-435 cells. Clinical & Experimental Metastasis, 21(2), 149-157.
51. Rivera, J.; Megias, D.; & Bravo, J. (2007). Proteomics-based strategy to delineate the molecular mechanisms of the metastasis suppressor gene BRMS1. Journal of Proteome Research, 6(10), 4006-4018.
52. Hedley, B. D.; Welch, D. R.; Allan, A. L.; Al-Katib, W.; Dales, D. W.; Postenka, C. O.; et al. (2008). Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1. International Journal of Cancer, 123(3), 526-534.
53. Samant, R. S.; Clark, D. W.; Fillmore, R. A.; Cicek, M.; Metge, B. J.; Chandramouli, K. H.; et al. (2007). Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation. Molecular Cancer, 6, 6.
54. Cicek, M.; Fukuyama, R.; Welch, D. R.; Sizemore, N.; & Casey, G. (2005). Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-κB activity. Cancer Research, 65(9), 3586-3595.
55. Cicek, M.; Fukuyama, R.; Cicek, M. S.; Sizemore, S.; Welch, D. R.; Sizemore, N.; et al. (2009). BRMS1 contributes to the negative regulation of uPA gene expression through recruitment of HDAC1 to the NF-kappaB binding site of the uPA promoter. Clinical & Experimental Metastasis, 26(3), 229-237.
56. Hurst, D. R.; Xie, Y.; Vaidya, K. S.; Mehta, A.; Moore, B. P.; Accavitti-Loper, M. A.; et al. (2008). Alterations of BRMS1-ARID4A interaction modify gene expression but still suppress metastasis in human breast cancer cells. Journal of Biological Chemistry, 283(12), 7438-7444.
57. Yang, J.; Zhang, B.; Lin, Y.; Yang, Y.; Liu, X.; & Lu, F. (2008). Breast cancer metastasis suppressor 1 inhibits SDF-1alpha-induced migration of non-small cell lung cancer by decreasing CXCR4 expression. Cancer Letters, 269(1), 46-56.
58. Edmonds, M. D.; Hurst, D. R.; Vaidya, K. S.; Stafford, L. J.; Chen, D.; & Welch, D. R. (2009). Breast cancer metastasis suppressor 1 coordinately regulates metastasis-associated microRNA expression. International Journal of Cancer, 125(8), 1778-1785.
59. Hurst, D. R.; Edmonds, M. D.; Scott, G. K.; Benz, C. C.; Vaidya, K. S.; & Welch, D. R. (2009). Breast cancer metastasis suppressor 1 BRMS1 up-regulates miR-146 that suppresses breast cancer metastasis. Cancer Research, 69(4), 1279-1283.
60. Liu, Y.; Smith, P. W.; & Jones, D. R. (2006). Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis. Molecular and Cellular Biology, 26(23), 8683-8696.
61. Taganov, K. D.; Boldin, M. P.; Chang, K. J.; & Baltimore, D. (2006). NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proceedings of the National Academy of Sciences of the United States of America, 103(33), 12481-12486.
62. Bhaumik, D.; Scott, G. K.; Schokrpur, S.; Patil, C. K.; Campisi, J.; & Benz, C. C. (2008). Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene, 27(42), 5643-5647.
63. Edmonds, M. D.; Hurst, D. R.; & Welch, D. R. (2009). Linking metastasis suppression with metastamiR regulation. Cell Cycle, 8(17), 2673-2675.
64. Hurst, D. R.; Edmonds, M. D.; & Welch, D. R. (2009). Metastamir: The field of metastasis-regulatory microRNA is spreading. Cancer Research, 69(19), 7495-7498.
65. Hurst, D. R.; Mehta, A.; Moore, B. P.; Phadke, P. A.; Meehan, W. J.; Accavitti, M. A.; et al. (2006). Breast cancer metastasis suppressor 1 (BRMS1) is stabilized by the Hsp90 chaperone. Biochemical and Biophysical Research Communications, 348(4), 1429-1435.
66. Rivera, J.; Megias, D.; & Bravo, J. (2010). Sorting nexin 6 interacts with breast cancer metastasis suppressor-1 and promotes transcriptional repression. Journal of Cellular Biochemistry, 111(6), 1464-1472.
67. Meehan, W. J.; Samant, R. S.; Hopper, J. E.; Carrozza, M. J.; Shevde, L. A.; Workman, J. L.; et al. (2004). Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription. Journal of Biological Chemistry, 279(2), 1562-1569.
68. Doyon, Y.; Cayrou, C.; Ullah, M.; Landry, A. J.; Cote, V.; Selleck, W.; et al. (2006). ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Molecular Cell, 21(1), 51-64.
69. Smith, K. T.; Martin-Brown, S. A.; Florens, L.; Washburn, M. P.; & Workman, J. L. (2010). Deacetylase inhibitors dissociate the histone-targeting ING2 subunit from the Sin3 complex. Chemistry and Biology, 17(1), 65-74.
70. Shiio, Y.; Rose, D. W.; Aur, R.; Donohoe, S.; Aebersold, R.; & Eisenman, R. N. (2006). Identification and characterization of SAP25, a novel component of the mSin3 corepressor complex. Molecular and Cellular Biology, 26(4), 1386-1397.
71. Le Guezennec, X.; Vermeulen, M.; & Stunnenberg, H. G. (2006). Molecular characterization of Sin3 PAH-domain interactor specificity and identification of PAH partners. Nucleic Acids Research, 34(14), 3929-3937.
72. Bantscheff, M.; Hopf, C.; Savitski, M. M.; Dittmann, A.; Grandi, P.; Michon, A. M.; et al. (2011). Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nature Biotechnology, 29(3), 255-265.
73. Nasmyth, K.; Stillman, D.; & Kipling, D. (1987). Both positive and negative regulators of HO transcription are required for mother-cell-specific mating-type switching in yeast. Cell, 48(4), 579-587.
74. Sternberg, P. W.; Stern, M. J.; Clark, I.; & Herskowitz, I. (1987). Activation of the yeast HO gene by release from multiple negative controls. Cell, 48(4), 567-577.
75. Yang, X. J.; & Seto, E. (2008). The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nature Reviews Molecular Cell Biology, 9(3), 206-218.
76. Chimonidou, M.; Strati, A.; Tzitzira, A.; Sotiropoulou, G.; Malamos, N.; Georgoulias, V.; et al. (2011). DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. Clinical Chemistry, 57(8), 1169-1177.
77. Hicks, D. G.; Yoder, B. J.; Short, S.; Tarr, S.; Prescott, N.; Crowe, J. P.; et al. (2006). Loss of BRMS1 protein expression predicts reduced disease-free survival in hormone receptor negative and HER2 positive subsets of breast cancer. Clinical Cancer Research, 12(22), 6702-6708.
78. Frolova, N.; Edmonds, M. D.; Bodenstine, T. M.; Seitz, R.; Johnson, M. R.; Feng, R.; et al. (2009). A shift from nuclear to cytoplasmic breast cancer metastasis suppressor 1 expression is associated with highly proliferative estrogen receptor-negative breast cancers. Tumour Biology, 30(3), 148-159.
79. Li, J.; Cheng, Y.; Tai, D.; Martinka, M.; Welch, D. R.; & Li, G. (2011). Prognostic significance of BRMS1 expression in human melanoma and its role in tumor angiogenesis. Oncogene, 30(8), 896-906.
80. Zhang, Z.; Yamashita, H.; Toyama, T.; Yamamoto, Y.; Kawasoe, T.; & Iwase, H. (2006). Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer. Clinical Cancer Research, 12(21), 6410-6414.
81. Steeg, P. S.; & Theodorescu, D. (2007). Metastasis: a therapeutic target for cancer. Nature Clinical Practice Oncology, 5(4), 206-219.
82. Eccles, S. A.; & Welch, D. R. (2007). Metastasis: recent discoveries and novel treatment strategies. Lancet, 369(9574), 1742-1757.
83. Dokmanovic, M.; Clarke, C.; & Marks, P. A. (2007). Histone deacetylase inhibitors: overview and perspectives. Molecular Cancer Research, 5(10), 981-989.
84. Martinez-Iglesias, O.; Ruiz-Llorente, L.; Sanchez-Martinez, R.; Garcia, L.; Zambrano, A.; & Aranda, A. (2008). Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clinical and Translational Oncology, 10(7), 395-398.
85. Coussens, L. M.; Fingleton, B.; & Matrisian, L. M. (2002). Cancer therapymatrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science, 295(5564), 2387-2392.
86. Farias, E. F.; Petrie, K.; Leibovitch, B.; Murtagh, J.; Chornet, M. B.; Schenk, T.; et al. (2010). Interference with Sin3 function induces epigenetic reprogramming and differentiation in breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 107(26), 11811-11816.
87. Siegel, R.; Ward, E.; Brawley, O.; & Jemal, A. (2011). Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: A Cancer Journal for Clinicians, 61(4), 212-236.
88. Lu, J.; Steeg, P. S.; Price, J. E.; Krishnamurthy, S.; Mani, S. A.; Reuben, J.; et al. (2009). Breast cancer metastasis: challenges and opportunities. Cancer Research, 69(12), 4951-4953.
89. Taylor, J.; Hickson, J.; Lotan, T.; Yamada, D. S.; & Rinker-Schaeffer, C. (2008). Using metastasis suppressor proteins to dissect interactions among cancer cells and their microenvironment. Cancer and Metastasis Reviews, 27(1), 67-73.
90. Smith, S. C.; & Theodorescu, D. (2009). Learning therapeutic lessons from metastasis suppressor proteins. Nature Reviews Cancer, 9(4), 253-264.
91. Dannenberg, J. H.; David, G.; Zhong, S.; van der Torre, J.; Wong, W. H.; & DePinho, R. A. (2005). mSin3A corepressor regulates diverse transcriptional networks governing normal and neoplastic growth and survival. Genes & Development, 19(13), 1581-1595.
92. Cowley, S. M.; Iritani, B. M.; Mendrysa, S. M.; Xu, T.; Cheng, P. F.; Yada, J.; et al. (2005). The mSin3A chromatin-modifying complex is essential for embryogenesis and T-cell development. Molecular and Cellular Biology, 25(16), 6990-7004.
93. McDonel, P.; Demmers, J.; Tan, D. W.; Watt, F.; & Hendrich, B. D. (2011). Sin3a is essential for the genome integrity and viability of pluripotent cells. Developmental Biology. doi: 10.1016/j.ydbio.2011.12.019.
94. David, G.; Grandinetti, K. B.; Finnerty, P. M.; Simpson, N.; Chu, G. C.; & DePinho, R. A. (2008). Specific requirement of the chromatin modifier mSin3B in cell cycle exit and cellular differentiation. Proceedings of the National Academy of Sciences of the United States of America, 105(11), 4168-4172.
95. Lagger, G.; O'Carroll, D.; Rembold, M.; Khier, H.; Tischler, J.; Weitzer, G.; et al. (2002). Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO Journal, 21(11), 2672-2681.
96. Montgomery, R. L.; Davis, C. A.; Potthoff, M. J.; Haberland, M.; Fielitz, J.; Qi, X.; et al. (2007). Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes & Development, 21(14), 1790-1802.
97. Dovey, O. M.; Foster, C. T.; & Cowley, S. M. (2010). Histone deacetylase 1 (HDAC1), but not HDAC2, controls embryonic stem cell differentiation. Proceedings of the National Academy of Sciences of the United States of America, 107(18), 8242-8247.
98. Wilting, R. H.; Yanover, E.; Heideman, M. R.; Jacobs, H.; Horner, J.; van der Torre, J.; et al. (2010). Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO Journal, 29(15), 2586-2597.
99. Zimmermann, S.; Kiefer, F.; Prudenziati, M.; Spiller, C.; Hansen, J.; Floss, T.; et al. (2007). Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice. Cancer Research, 67(19), 9047-9054.
100. Guan, J. S.; Haggarty, S. J.; Giacometti, E.; Dannenberg, J. H.; Joseph, N.; Gao, J.; et al. (2009). HDAC2 negatively regulates memory formation and synaptic plasticity. Nature, 459(7243), 55-60.
101. Alland, L.; David, G.; Shen-Li, H.; Potes, J.; Muhle, R.; Lee, H. C.; et al. (2002). Identification of mammalian Sds3 as an integral component of the Sin3/histone deacetylase corepressor complex. Molecular and Cellular Biology, 22(8), 2743-2750.
102. David, G.; Turner, G. M.; Yao, Y.; Protopopov, A.; & DePinho, R. A. (2003). mSin3-associated protein, mSds3, is essential for pericentric heterochromatin formation and chromosome segregation in mammalian cells. Genes & Development, 17(19), 2396-2405.
103. David, G.; Dannenberg, J. H.; Simpson, N.; Finnerty, P. M.; Miao, L.; Turner, G. M.; et al. (2006). Haploinsufficiency of the mSds3 chromatin regulator promotes chromosomal instability and cancer only upon complete neutralization of p53. Oncogene, 25(56), 7354-7360.
104. Wu, M. Y.; Tsai, T. F.; & Beaudet, A. L. (2006). Deficiency of Rbbp1/Arid4a and Rbbp1l1/Arid4b alters epigenetic modifications and suppresses an imprinting defect in the PWS/AS domain. Genes & Development, 20(20), 2859-2870.
105. Kichina, J. V.; Zeremski, M.; Aris, L.; Gurova, K. V.; Walker, E.; Franks, R.; et al. (2006). Targeted disruption of the mouse ing1 locus results in reduced body size, hypersensitivity to radiation and elevated incidence of lymphomas. Oncogene, 25(6), 857-866.
106. Saito, M.; Kumamoto, K.; Robles, A. I.; Horikawa, I.; Furusato, B.; Okamura, S.; et al. (2010). Targeted disruption of Ing2 results in defective spermatogenesis and development of soft-tissue sarcomas. PLoS One, 5(11), e15541.